Home/Filings/4/0001193125-25-204233
4//SEC Filing

Lee Tien-Li 4

Accession 0001193125-25-204233

CIK 0001774857other

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 6:15 AM ET

Size

7.6 KB

Accession

0001193125-25-204233

Insider Transaction Report

Form 4
Period: 2025-09-15
Lee Tien-Li
DirectorChief Executive Officer10% Owner
Transactions
  • Purchase

    Common Stock

    2025-09-15$9.51/sh+6,500$61,8191,539,884 total
  • Purchase

    Common Stock

    2025-09-15$9.94/sh+3,500$34,8051,543,384 total
Holdings
  • Common Stock

    (indirect: By Spouse)
    1,474,028
Footnotes (2)
  • [F1]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.9045 to $9.89 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F2]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.93 to $9.9798 per share, inclusive. The reporting person undertakes to provide Aardvark, any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Documents

1 file

Issuer

Aardvark Therapeutics, Inc.

CIK 0001774857

Entity typeother

Related Parties

1
  • filerCIK 0001940120

Filing Metadata

Form type
4
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 6:15 AM ET
Size
7.6 KB